Despite being high-value therapeutic targets, G protein-coupled receptors (GPCRs) have been largely intractable to conventional antibody discovery technologies. Here, we present a case study in which we leveraged our discovery and development engine to find diverse antibodies against an established GPCR target, chemokine receptor 8 (CCR8).